ENRUHE
PF-Atlas › Clinical Trials › NCT06460506

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

ELX/TEZ/IVA · Phase 3

Registry ID
NCT06460506
Phase
Phase 3
Status
Active, not recruiting
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2024-11-21

About this trial

ELX/TEZ/IVA is evaluated in NCT06460506, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Active, not recruiting.

View NCT06460506 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761
Medical disclaimer. This page summarizes public trial data for NCT06460506 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.